Memokath-051 stent for ureteric obstruction: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 13 September 2022.
Search results
486 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma [ID1685]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 31 August 2022.
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development [GID-MT567] Expected publication date: TBC
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: TBC
-
GID-MT568 Magtrace and Sentimag for locating sentinel lymph nodes
In development [GID-MT568] Expected publication date: 05 October 2022
-
GID-MT570 AposHealth for osteoarthritis (OA) of the knee
In development [GID-MT570] Expected publication date: 31 March 2023
-
GID-MT562 FibroScan for assessing liver fibrosis and cirrhosis in primary or community care
In development [GID-MT562] Expected publication date: 21 December 2022
-
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
In development [GID-MT563] Expected publication date: TBC
-
GID-MT575 GaitSmart rehabilitation exercise programme
In development [GID-MT575] Expected publication date: TBC
-
GID-MT565 Optilume for recurrent bulbar urethral strictures
In development [GID-MT565] Expected publication date: 28 November 2022
-
Digital cognitive behavioural therapy for children and young people with symptoms of anxiety and low mood
In development [GID-MT580] Expected publication date: TBC
-
Memokath-051 stent for ureteric obstruction
In development [GID-MT569] Expected publication date: 07 December 2022
-
GID-MT566 Faecal microbiota transplant for recurrent Clostridioides difficile infection
In development [GID-MT566] Expected publication date: 30 August 2022
-
GID-MT564 GreenLight XPS for treating benign prostatic hyperplasia
In development [GID-MT564] Expected publication date: 28 November 2022
-
Guided digital therapies for adults with depression
In development [GID-MT588] Expected publication date: TBC
-
Guided digital therapies for adults with anxiety disorder
In development [GID-MT589] Expected publication date: TBC
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: 31 May 2023
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
In development [GID-TA10179] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [Review of TA611] [ID4069]
In development [GID-TA10985] Expected publication date: TBC
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
In development [GID-TA10979] Expected publication date: TBC
-
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant [ID3969]
In development [GID-TA10852] Expected publication date: TBC
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
In development [GID-TAG363] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260
In development [GID-TA10309] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
In development [GID-TA10490] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
In development [GID-TA10492] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
In development [GID-TA10571] Expected publication date: 25 August 2021
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal [TA714] Published: 14 July 2021